Modulim
PrivateLast Round
Grant
May 18, 2023
Total Funding Raised
$16.11M
Company Overview
Modulim operates in Healthcare & Life Sciences and is based in Irvine, California. Its latest recorded funding round was a Grant round in May 2023.
Modulim is a medical device company that develops and commercializes non-invasive optical imaging platforms powered by spatial frequency domain imaging (SFDI) to assess microvascular tissue health for the prevention and management of chronic wound complications.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Medical Imaging, Healthcare Analytics
Business Model
B2B
Customer Profile
Hardware + Subscription, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Modulim Comparables
Compare Modulim with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MIMOSA Diagnostics | 84% | |
| VOTIS Subdermal Imaging Technologies | 82% | |
| Kent Imaging | 82% |
For institutional investors. Book with your work email.
Modulim Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | May 18, 2023 | ||||
| Series C | Dec 8, 2020 | ||||
| Debt | Apr 27, 2020 | ||||
| Series B | Jan 23, 2019 | ||||
| Grant | Nov 17, 2017 | ||||
Series A | Nov 17, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Modulim Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Arthritis and Musculoskeletal and Skin Diseases | Grant |
| Grey Sky Venture Partners | Series B, Series A |
| NIH RADx | Grant |
| Cove Fund | Seed |
| Fresenius Medical Care Ventures | Series A, Series B |
| Mitsubishi UFJ Capital | Series A, Series B |
| Pangaea Ventures | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- May 18, 2023
$3M grant from the United States Army Medical Materiel Development Activity.
- Dec 8, 2020
Raised Series C round
For institutional investors. Book with your work email.
Modulim Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Modulim's valuation, stock price, and market status.
Is Modulim a public or private company?
Modulim is a private company.
What is the current stock price of Modulim?
Modulim is a private company, so its shares have no public market price. Caplight tracks Modulim's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Modulim worth (valuation)?
Valuation information for Modulim is not publicly available.
Can I buy Modulim stock?
Modulim shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Modulim's last funding round?
Modulim's most recent funding round was Grant on May 18, 2023.
Who are the main investors in Modulim?
Key investors in Modulim include National Institute of Arthritis and Musculoskeletal and Skin Diseases, Grey Sky Venture Partners, NIH RADx, Cove Fund, Pangaea Ventures.
Will Modulim IPO soon?
No public IPO plans have been announced for Modulim.
How can I track Modulim secondary market activity?
Caplight tracks bids, offers, and trades in Modulim's shares on secondary markets.